On Tuesday, Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) opened lower -1.37% from the last session, before settling in for the closing price of $273.55. Price fluctuations for ALNY have ranged from $144.73 to $304.39 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 63.53%. Company’s average yearly earnings per share was noted 58.95% at the time writing. With a float of $124.65 million, this company’s outstanding shares have now reached $130.31 million.
Let’s determine the extent of company efficiency that accounts for 2230 employees. In terms of profitability, gross margin is 86.01%, operating margin of -4.91%, and the pretax margin is -15.13%.
Alnylam Pharmaceuticals Inc (ALNY) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Alnylam Pharmaceuticals Inc is 4.40%, while institutional ownership is 95.56%. The most recent insider transaction that took place on Mar 24 ’25, was worth 1,633,500. In this transaction CMO & EVP Dev & Med Affairs of this company sold 5,445 shares at a rate of $300.00, taking the stock ownership to the 20,221 shares. Before that another transaction happened on Mar 21 ’25, when Company’s CMO & EVP Dev & Med Affairs sold 4,321 for $285.00, making the entire transaction worth $1,231,485. This insider now owns 20,221 shares in total.
Alnylam Pharmaceuticals Inc (ALNY) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 58.95% per share during the next fiscal year.
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) Trading Performance Indicators
Check out the current performance indicators for Alnylam Pharmaceuticals Inc (ALNY). In the past quarter, the stock posted a quick ratio of 2.98. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 14.98.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.09, a number that is poised to hit -0.71 in the next quarter and is forecasted to reach 1.80 in one year’s time.
Technical Analysis of Alnylam Pharmaceuticals Inc (ALNY)
Looking closely at Alnylam Pharmaceuticals Inc (NASDAQ: ALNY), its last 5-days average volume was 1.2 million, which is a jump from its year-to-date volume of 0.88 million. As of the previous 9 days, the stock’s Stochastic %D was 87.37%. Additionally, its Average True Range was 12.54.
During the past 100 days, Alnylam Pharmaceuticals Inc’s (ALNY) raw stochastic average was set at 67.28%, which indicates a significant decrease from 86.84% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 31.49% in the past 14 days, which was lower than the 49.79% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $249.94, while its 200-day Moving Average is $259.06. However, in the short run, Alnylam Pharmaceuticals Inc’s stock first resistance to watch stands at $274.98. Second resistance stands at $280.15. The third major resistance level sits at $283.83. If the price goes on to break the first support level at $266.13, it is likely to go to the next support level at $262.45. Now, if the price goes above the second support level, the third support stands at $257.28.
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) Key Stats
There are currently 130,388K shares outstanding in the company with a market cap of 35.18 billion. Presently, the company’s annual sales total 2,248 M according to its annual income of -278,160 K. Last quarter, the company’s sales amounted to 594,190 K and its income totaled -57,480 K.
